# BPC-157 recovery research: human pilots and animal studies > BPC-157 recovery research read in two tiers: three small human pilots (IV safety, intra-articular knee, intravesical cystitis) over the rodent tendon and tissue-repair literature. The top tier is three small human pilots. The lower tier is the rodent recovery record. Read in that order, the BPC-157 recovery research is honest about what is human evidence and what is not. ## BPC-157 recovery research begins with three small human pilots BPC-157 recovery research in humans is, as of 2025, three small uncontrolled pilots — and naming them precisely is the point of this page. The first is a 2025 intravenous safety pilot: BPC-157 given by infusion up to `20 mg` in two healthy adults was well tolerated, with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers [5]. The second is a 2021 intra-articular case series reporting reduced knee pain across several pain types after injection into the joint — uncontrolled, no comparator [7]. The third is a 2024 intravesical pilot in 12 interstitial-cystitis patients: a single `10 mg` dose during cystoscopy was associated with symptom resolution in most patients, again with no reported adverse events [8]. That is the entire top tier. A 2025 narrative review surveyed the field and concluded that despite broad preclinical support, human data are extremely limited, rigorous large-scale trials are lacking, and BPC-157 should be treated as investigational [6]. Everything below this is animal or in-vitro work. ## BPC-157 and Tendon Healing Studies The tendon-healing studies are the strongest preclinical recovery signal. In a fully transected rat Achilles tendon, BPC-157 — administered at `10 microg`, `10 ng`, or `10 pg` per rat, intraperitoneally once daily — accelerated healing across biomechanical, functional, microscopic, and macroscopic measures, and stimulated tendocyte outgrowth in vitro [1]. The treated tendons showed better collagen organization and restored integrity versus untreated controls [1]. The mechanistic bridge to tendon is plausible: BPC-157 is pro-angiogenic via VEGFR2-Akt-eNOS signaling [3] and is reported to up-regulate the growth-hormone receptor in tendon fibroblasts. What does not yet exist is a controlled human tendon trial. The leap from "restored load-to-failure in a rat Achilles" to a human outcome has not been tested, and this page does not make it for you. ## BPC-157 Benefits Reported in the Research Literature The benefits reported in the BPC-157 literature cluster around tissue protection and repair. In rats, BPC-157 reduced gastric-ulcer area with an inhibition ratio of 45.7-65.6% at the higher doses, and intramuscular delivery outperformed intragastric [4]. It healed colocutaneous fistulas in rats and, as PL14736, was described as safe in early IBD trials [9]. Recent rodent work reports protection of distant organs — liver, kidney, and lung — in acute pancreatitis [11], and resolution of a tracheocutaneous fistula attributed to the nitric-oxide system [10]. Read these as preclinical benefits. They describe what the molecule did in animals and cells, not a clinical recommendation. Common online claims — weight loss, muscle building, testosterone increase — are not supported by the published evidence and should be treated skeptically [6]. ## BPC-157 Side Effects and Safety Signals in the Studies The reported safety signal is reassuring within a very small dataset. The 2025 IV pilot recorded no adverse events and no measurable biomarker changes across cardiac, hepatic, renal, thyroid, and glucose panels in two adults [5]. Rodent work even reports the peptide protecting the liver, kidneys, and lungs in injury models [11], and describes beneficial effects following various intoxications [12]. The honest reading is that the absence of long-term, large-N human safety data means the side-effect profile of BPC-157 is genuinely unknown [6]. "No adverse events in two people" is not the same as "safe." Because BPC-157 is widely distributed through non-regulated channels, product identity, purity, and dose are also unverified outside formal studies [6]. ## Does BPC-157 really work? Most BPC-157 evidence is preclinical, so the honest answer is that efficacy in humans is unestablished. A 2025 narrative review found only three small human pilot studies and concluded that rigorous large-scale trials are lacking [6]. The animal recovery data are large and reproducible [1][4], but reproducibility in rodents is not proof of a human effect. ## Has anyone used BPC-157 to heal an injury? Published human use is limited to small uncontrolled pilots. An intra-articular case series reported reduced knee pain across several pain types after injection into the joint [7], and a 12-patient intravesical pilot reported interstitial-cystitis symptom improvement [8]. Both lacked a comparator group, so they signal feasibility, not proven injury-healing. ## Is BPC-157 worth it for tendon recovery? Animal Achilles-tendon work shows accelerated, well-organized healing at doses near `10 microg/kg` in rats [1], but human tendon-recovery evidence is anecdotal. No controlled human tendon trial of BPC-157 exists, so any "worth it" judgment for a person is made without clinical efficacy data. ## Can BPC-157 heal arthritis? An uncontrolled human case series reported improvement across multiple types of knee pain after intra-articular BPC-157 injection [7]. That is a preliminary symptom signal, not controlled arthritis-efficacy evidence — there was no comparator group and no structural-outcome measure, so it cannot establish that BPC-157 heals arthritis. --- A two-tier readout of the BPC-157 record — the human pilots logged above the animal evidence, sourced line by line, with no clinic behind the console and nothing here for sale.